Gilead, a science company which develops innovative treatments with the mission of bringing the best solutions to life-threatening diseases, has started to produce its life-saving strategic medicines for Hepatitis and HIV diseases in Turkey.
With this localization investment of approximately $60 million Gilead, which started domestic production with support of Investment Office of the Presidency of Republic of Türkiye and in cooperation with Pharmactive, will thus contribute around 70 percent to the volume of domestic product. Turkey has become one of Gilead’s production bases along with Germany, Canada and Ireland, for these products.
